Toshinobu Hayashi1,2, Mototsugu Shimokawa3, Takanori Miyoshi4, Yoko Toriyama4, Chiaki Yokota5, Jun Taniguchi6, Kiyonori Hanada7, Kyouichi Tsumagari8, Noriko Okubo9, Yoshimichi Koutake10, Kohei Sakata11, Yosei Kawamata12, Takashi Goto13, Yasufumi Tsurusaki14, Makiko Koyabu15. 1. Department of Pharmacy, Clinical Research Institute, National Kyushu Medical Center, 1-8-1, Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan. nenten-ph@umin.org. 2. Department of Pharmacy, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan. nenten-ph@umin.org. 3. Cancer Biostatistics Laboratory, Clinical Research Institute, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan. 4. Department of Pharmacy, National Hospital Organization Beppu Medical Center, 1473 Uchikamado, Beppu, Oita, 874-0011, Japan. 5. Department of Pharmacy, National Hospital Organization Nagasaki Medical Center, 2-1001-1 Kubara, Omura, Nagasaki, 856-8562, Japan. 6. Department of Pharmacy, National Hospital Organization Ureshino Medical Center, 2436 Oazashimojukuhei, Ureshino-cho, Ureshino, Saga, 843-0393, Japan. 7. Department of Pharmacy, National Hospital Organization Kumamoto Saishunso National Hospital, 2659 Suya, Koushi, Kumamoto, 861-1196, Japan. 8. Department of Pharmacy, National Hospital Organization Miyakonojo Medical Center, 5033-1 Iwayoshi-cho, Miyakonojo, Miyazaki, 885-0014, Japan. 9. Department of Pharmacy, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan. 10. Department of Pharmacy, National Hospital Organization Fukuoka National Hospital, 1-39-4, Yakatabaru, Minami-ku, Fukuoka, 811-1394, Japan. 11. Department of Pharmacy, National Hospital Organization Kumamoto South National Hospital, 2338 Toyofuku, Matsubase-cho, Uki, Kumamoto, 869-0593, Japan. 12. Department of Pharmacy, National Hospital Organization Kagoshima Medical Center, 8-1, Shiroyama-cho, Kagoshima, 892-0853, Japan. 13. Department of Pharmacy, National Hospital Organization Kokura Medical Center, 10-1, Harugaoka, Kokuraminami-ku, Kitakyushu, 802-8533, Japan. 14. Department of Pharmacy, National Hospital Organization Saga National Hospital, 1-20-1, Hinode, Saga, 849-8577, Japan. 15. Department of Pharmacy, Clinical Research Institute, National Kyushu Medical Center, 1-8-1, Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan.
Abstract
PURPOSE: The incidence of and the risk factors for nausea and vomiting in patients undergoing low emetic risk chemotherapy (LEC) are unclear. The aim of the study was to provide information on these topics by performing a multicenter, observational, prospective study. METHODS: The study consisted of patients who were administered first-time LEC that was consistent or inconsistent with current guidelines. Using the visual analog scale, patients recorded their daily food intake and the occurrence and severity of nausea over a 5-day treatment period. RESULTS: The overall incidence of chemotherapy-induced nausea and vomiting did not differ significantly between patients undergoing guideline-consistent (n = 89) or guideline-inconsistent (n = 121) prophylaxis (30.3 vs. 22.3%, respectively; P = 0.19). Logistic regression analysis identified a history of nausea and LEC other than taxanes as independent risk factors associated with nausea and vomiting in patients undergoing LEC. The mean daily visual analog scale scores for nausea severity and a decrease in food intake were <25 mm throughout the entire observation period. CONCLUSIONS: Guideline-consistent prophylaxis appeared to control nausea and vomiting effectively in patients undergoing LEC. However, patients with a history of nausea and receiving LEC other than taxanes should be carefully observed and treatment should be adjusted according to their symptoms.
PURPOSE: The incidence of and the risk factors for nausea and vomiting in patients undergoing low emetic risk chemotherapy (LEC) are unclear. The aim of the study was to provide information on these topics by performing a multicenter, observational, prospective study. METHODS: The study consisted of patients who were administered first-time LEC that was consistent or inconsistent with current guidelines. Using the visual analog scale, patients recorded their daily food intake and the occurrence and severity of nausea over a 5-day treatment period. RESULTS: The overall incidence of chemotherapy-induced nausea and vomiting did not differ significantly between patients undergoing guideline-consistent (n = 89) or guideline-inconsistent (n = 121) prophylaxis (30.3 vs. 22.3%, respectively; P = 0.19). Logistic regression analysis identified a history of nausea and LEC other than taxanes as independent risk factors associated with nausea and vomiting in patients undergoing LEC. The mean daily visual analog scale scores for nausea severity and a decrease in food intake were <25 mm throughout the entire observation period. CONCLUSIONS: Guideline-consistent prophylaxis appeared to control nausea and vomiting effectively in patients undergoing LEC. However, patients with a history of nausea and receiving LEC other than taxanes should be carefully observed and treatment should be adjusted according to their symptoms.
Authors: Maurizio Tonato; Rebecca A Clark-Snow; David Osoba; Albano Del Favero; Enzo Ballatori; Sussanne Borjeson Journal: Support Care Cancer Date: 2004-11-18 Impact factor: 3.603
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: Alexander Molassiotis; Matti Aapro; Mario Dicato; Pere Gascon; Sylvia A Novoa; Nicolas Isambert; Thomas A Burke; Anna Gu; Fausto Roila Journal: J Pain Symptom Manage Date: 2013-09-24 Impact factor: 3.612
Authors: Lee Schwartzberg; Gary Morrow; Sanjeev Balu; Chris Craver; Julie Gayle; David Cox Journal: Curr Med Res Opin Date: 2011-06-22 Impact factor: 2.580
Authors: Ian Olver; Christina H Ruhlmann; Franziska Jahn; Lee Schwartzberg; Bernardo Rapoport; Cynthia N Rittenberg; Rebecca Clark-Snow Journal: Support Care Cancer Date: 2016-08-30 Impact factor: 3.603
Authors: Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan Journal: J Clin Oncol Date: 2003-10-14 Impact factor: 44.544
Authors: A Molassiotis; M P Saunders; J Valle; G Wilson; P Lorigan; A Wardley; E Levine; R Cowan; J Loncaster; C Rittenberg Journal: Support Care Cancer Date: 2007-10-10 Impact factor: 3.603